2026-06-02T00:13:49Z https://icatplus.esrf.fr/oaipmh/request

oai:icatplus.esrf.fr:inv/2025026699 2025-05-01T06:00:09.935Z

4.2 EI 10.15151/ESRF-ES-2025026699 Dihia MOUSSAOUI Dihia Moussaoui 0000-0002-1605-9619 Matthias MÜLLER Matthias Müller 0000-0002-1529-8933 Matthias MÜLLER Matthias Müller 0000-0002-1529-8933 Andrea SCRIMA Andrea Scrima 0000-0003-2760-611X Andrea SCRIMA Andrea Scrima 0000-0003-2760-611X Danilo DANGELO Danilo Dangelo 0009-0006-5038-3865 Danilo DANGELO Danilo Dangelo 0009-0006-5038-3865 Janina NIGGENABER Janina Niggenaber 0000-0003-2942-263X Janina NIGGENABER Janina Niggenaber 0000-0003-2942-263X Raphael GASPER-SCHOENENBRUECHER Raphael Gasper-Schoenenbruecher 0000-0002-7780-0773 Raphael GASPER-SCHOENENBRUECHER Raphael Gasper-Schoenenbruecher 0000-0002-7780-0773 Example Institute 2028 Data from large facility measurement 2025-04-30T07:30:00Z/2025-05-01T06:00:00Z 2025-05-01T06:00:00Z I CC-BY-4.0 Small molecules represent powerful tools to dissect physiological and pathological states of signaling pathways, yet require characterization through X-ray crystallography. This proposal encompasses the investigation of new classes of small molecules that target difficult proteins and non-typical binding sites. This includes the development of supramolecular compounds or cyclic peptides to address “non-druggable" proteins. The main collaborative research fields are tackling Ras protein signaling with structure-guided ligand design, developing inhibitors of the Ras-binding protein PDEd, screening of a novel sp3-enriched fragment library or targeting genetic regulators. Cellular signaling will also be addressed through the structural analysis of deubiquitinating enzymes or regulators of the kinetochore. Finally, we plan to crystallize membrane proteins including GPCRs in order to understand their biological function, characterize their ligand specificity and develop novel regulators.